HomeQuestion

How should poorly differentiated breast neuroendocrine carcinoma be treated in the neoadjuvant or adjuvant setting?

Join the Discussion

Discuss the cases and questions guidelines don't cover.

Related Questions

Considering the results of the I-SPY2 trial discussed at ASCO 2025, what would be your approach to treating a T1cN0 (tumor 1.5-1.9cm) young, fit patient? NACT THP x4 or surgery upfront?

Would you add pertuzumab to adjuvant therapy for a premenopausal female with HR+, HER2+ IDC with N1mic disease?

What additional risk features, if any, would sway you to offer chemotherapy in premenopausal women with ER+ HER2- node positive patients whose Oncotype is < 11?

Would you offer adjuvant ribociclib to a postmenopausal female with ER+ luminal A, node+ breast cancer pT1cN1a grade 2 that didn't require chemotherapy per Oncotype, but met NATALEE inclusion criteria?

How would you treat a patient with end-stage renal disease, a germline BRCA1 mutation, and pT1c pN0 TNBC s/p mastectomy?

Evidence Meets Expertise

For Physicians

Mednet AI
Community

Company

About
Careers
Publications
Blog

Support

FAQs
Code of Conduct
AI Community Guidelines
Contact Us
Programs

Legal

Privacy Policy
Terms of Service

© 2026 Mednet Inc. All rights reserved.